• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: Director Huffines Robert Luther was granted 151 shares, increasing direct ownership by 7% to 2,449 units (SEC Form 4)

    7/7/26 4:41:44 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care
    Get the next $PODD alert in real time by email
    SEC FORM 4/ASEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Huffines Robert Luther

    (Last)(First)(Middle)
    C/O INSULET CORPORATION
    100 NAGOG PARK

    (Street)
    ACTON MASSACHUSETTS 01720

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    INSULET CORP [ PODD ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    06/30/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    07/02/2026
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Common Stock06/30/2026A151(1)(2)A$152.25(2)2,449D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    1. These are deferred common stock units ("Deferred Units") received in lieu of cash compensation pursuant to the Company's Deferred Compensation Plan for Non-Employee Directors. The Deferred Units will be converted into shares of Company common stock on a one-for-one basis upon distribution, with the value of any fractional shares paid in cash. Distribution of shares of common stock occurs, at the election of the director, either in a lump sum or in substantially equal annual installments pursuant to the Company's Deferred Compensation Plan for Non-Employee Directors.
    2. Due to an administrative error, the wrong price per share was used to calculate the number of Deferred Units reported in the original Form 4. Accordingly, this amendment is being filed to correct the number of Deferred Units acquired (151 rather than 144 as originally reported) and the price per Deferred Unit ($152.25 rather than $159.79 as originally reported).
    /s/ Patricia K. Dolan, attorney-in-fact07/07/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $PODD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PODD

    DatePrice TargetRatingAnalyst
    6/23/2026$190.00Buy
    Deutsche Bank
    5/20/2026Outperform
    William Blair
    4/24/2026$220.00Buy → Neutral
    Rothschild & Co Redburn
    4/7/2026$230.00Buy → Neutral
    Citigroup
    1/27/2026$294.00Hold
    TD Cowen
    1/12/2026$274.00Overweight → Equal Weight
    Barclays
    12/16/2025$370.00Outperform
    Evercore ISI
    11/19/2025$400.00Neutral → Buy
    UBS
    More analyst ratings

    $PODD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Insulet Partners with Calm to Bring Mindfulness and Well-Being Tools to the Diabetes Community, Featuring a New Sleep Story Narrated by Lila Moss

    The partnership introduces The Mind in Range Collection, a set of tailored mindfulness resources available at no cost to the diabetes community, including a meditation series, a breathing exercise, and a new Calm Sleep Story narrated by Omnipod® user and fashion model Lila Moss, designed to help listeners unwind and feel supported With 359 million people worldwide living with an anxiety disorder1, and people with diabetes being 20% more likely to develop anxiety2, this initiative reinforces Insulet’s commitment to whole-person care and positions mental health as essential to diabetes management The integrated content collaboration is the first-of-its-kind between Calm and a MedTe

    7/14/26 3:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Accelerates Global Growth with Launch of Omnipod® 5 and Omnipod Discover™ in Spain, Expanding Access to Tubeless Diabetes Technology

    Omnipod 5 Automated Insulin Delivery System now available in 20 countries worldwide New web-based data platform Omnipod Discover simplifies diabetes insights for users, caregivers, and healthcare professionals Omnipod 5 launch in Spain is compatible with Abbott and Dexcom continuous glucose monitoring systems Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the commercial launch of its Omnipod 5 Automated Insulin Delivery System and its proprietary data management system Omnipod Discover™ in Spain, the Company’s newest European market. Spain is the 26th country whe

    7/6/26 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet to Announce Second Quarter 2026 Financial Results on August 5, 2026

    Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the second quarter of 2026 on Wednesday, August 5, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or

    7/1/26 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $PODD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Deutsche Bank initiated coverage on Insulet with a new price target

    Deutsche Bank initiated coverage of Insulet with a rating of Buy and set a new price target of $190.00

    6/23/26 7:56:18 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    William Blair resumed coverage on Insulet

    William Blair resumed coverage of Insulet with a rating of Outperform

    5/20/26 8:53:26 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet downgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn downgraded Insulet from Buy to Neutral and set a new price target of $220.00

    4/24/26 8:03:49 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $PODD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Stonesifer Timothy C. bought $400,393 worth of shares (2,790 units at $143.51), increasing direct ownership by 45% to 9,041 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    6/4/26 4:25:37 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Director Weatherman Elizabeth H bought $497,490 worth of shares (3,450 units at $144.20), increasing direct ownership by 50% to 10,352 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    6/3/26 4:19:18 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Director Minogue Michael R bought $499,847 worth of shares (2,030 units at $246.23) (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    2/26/26 7:05:23 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $PODD
    SEC Filings

    View All

    Insulet Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - INSULET CORP (0001145197) (Filer)

    6/25/26 7:06:41 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    SEC Form SD filed by Insulet Corporation

    SD - INSULET CORP (0001145197) (Filer)

    5/28/26 4:05:39 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - INSULET CORP (0001145197) (Filer)

    5/26/26 4:06:27 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $PODD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Huffines Robert Luther was granted 151 shares, increasing direct ownership by 7% to 2,449 units (SEC Form 4)

    4/A - INSULET CORP (0001145197) (Issuer)

    7/7/26 4:41:44 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Director Mazelsky Jonathan Jay was granted 1,355 shares (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    7/2/26 4:12:30 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    New insider Mazelsky Jonathan Jay claimed no ownership of stock in the company (SEC Form 3)

    3 - INSULET CORP (0001145197) (Issuer)

    7/2/26 4:10:28 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $PODD
    Leadership Updates

    Live Leadership Updates

    View All

    Insulet Announces Appointment of Jonathan J. Mazelsky to its Board of Directors

    Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Jonathan ("Jay") Mazelsky to the Company’s Board of Directors, effective July 1, 2026. Mr. Mazelsky joins the Board as an independent director. "We are pleased to welcome Jay to Insulet’s Board of Directors," said President and CEO Ashley McEvoy. "Jay has a strong track record of translating science into solutions to drive growth and create significant and enduring shareholder value. His background and expertise will be integral as Insulet continues to expand access and further strengthen Omnipod’s leaders

    6/25/26 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Appoints Mike Panos as Chief Commercial Officer

    Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Mike Panos as Executive Vice President, Chief Commercial Officer, effective immediately. In this role, Mr. Panos will lead Insulet's global commercial organization, reporting to President and Chief Executive Officer Ashley McEvoy. He will also be a member of the Executive Leadership Team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330524787/en/ "We have a significant growth opportunity in front of us, driven by strong clinical outcomes

    3/30/26 8:30:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Announces Appointment of Robert L. Huffines to its Board of Directors

    Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Robert ("Robbie") L. Huffines, a former Global Chair of Investment Banking at JP Morgan Chase & Co., to the Company's board of directors, effective October 31, 2025. Mr. Huffines joins the board as an independent director and will serve on the board's Audit Committee. "We are honored to welcome Robbie to Insulet's Board of Directors," said Timothy Scannell, Chairman of the Board. "Robbie brings more than three decades of distinguished experience advising healthcare companies at one of the world's leading f

    10/23/25 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $PODD
    Financials

    Live finance-specific insights

    View All

    Insulet to Announce Second Quarter 2026 Financial Results on August 5, 2026

    Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the second quarter of 2026 on Wednesday, August 5, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or

    7/1/26 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Reports First Quarter 2026 Results

    Raises Full Year Total Company Revenue Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended March 31, 2026. First Quarter Financial Highlights: Revenue of $761.7 million, up 33.9%, or 30.1% in constant currency1, and exceeded the high end of the Company's guidance range of 25% - 27% at constant currency rates Total Omnipod revenue of $758.4 million, rose 36.9%, or 33.0% in constant currency U.S. Omnipod revenue of $515.6 million, increased 28.3% International Omnipod revenue of $242.9 million, increased 59.4

    5/6/26 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet to Announce First Quarter 2026 Financial Results on May 6, 2026

    Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the first quarter of 2026 on Wednesday, May 6, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929

    4/1/26 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $PODD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Insulet Corporation

    SC 13G/A - INSULET CORP (0001145197) (Subject)

    11/12/24 12:53:28 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Insulet Corporation

    SC 13G/A - INSULET CORP (0001145197) (Subject)

    10/7/24 11:37:08 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Insulet Corporation (Amendment)

    SC 13G/A - INSULET CORP (0001145197) (Subject)

    2/13/24 5:06:23 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care